Interactive Brokers Appointed International Broker for Sinopac Securities
16.2.2023 09:00:00 EET | Business Wire | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced its appointment as the primary international broker for Sinopac Securities today. Institutional and retail clients of Sinopac can trade US stocks, ETFs, and Fixed Income instruments while also accessing over 90 stock markets worldwide through Interactive Brokers. This initiative between Interactive Brokers LLC and Sinopac strengthens Interactive Brokers’ footprint in the APAC region and adds Taiwan to the over 200 countries and territories worldwide where the company services clients.
“We are pleased to work with Sinopac and bring Interactive Brokers’ global trading capabilities and expertise to Taiwan,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “We recognize the advantage of working with a leading broker with local experience and look forward to serving the needs of this important market and its investors.”
Taiwanese investors will benefit from Interactive Brokers’ powerful trading platforms and advanced technology and tools. Interactive Brokers offers clients the ability to trade fractional shares of eligible US and European stocks as well as ETFs and can accommodate over 100 order types, including algorithmic trading, which is currently unavailable through other brokers in Taiwan. Clients can trade select US ETFs 23½ hours a day, five days a week through Overnight Trading Hours on the IBKR Eos ATS (“IBEOS”). With Overnight Trading Hours, investors across Asia can access US Equity Markets during their trading day and respond to market-moving news at almost any time. The collaboration with Sinopac also enables clients of Interactive Brokers to trade Taiwanese stocks through Sinopac Securities.
Introducing Brokers worldwide use Interactive Brokers’ Prime Broker services to help manage their businesses with efficiency and serve their clients at a lower cost. Through Interactive Brokers, Introducing Brokers can reduce their operational, brokerage, and clearing costs while gaining electronic market access worldwide with the company’s professional, white-branded trading technology. Interactive Brokers’ turnkey solution covers trading, clearing, reporting, and billing and provides the following advantages:
- Support for global regulatory reporting
- Account funding and trading in up to 26 currencies
- Access to stocks, options, futures, currencies, bonds, and funds in over 150 markets from a single unified platform
- No ticket charges, no minimums, and no technology, software, platform, or reporting fees
- Free client relationship management tools
For additional information about Interactive Brokers’ Introducing Broker platform, please visit:
US and Countries Served by IB LLC: https://www.interactivebrokers.com/en/accounts/broker.php
Canada: https://www.interactivebrokers.ca/en/accounts/broker.php
UK: https://www.interactivebrokers.co.uk/en/accounts/broker.php
Western Europe: https://www.interactivebrokers.ie/en/accounts/broker-ie.php
Central Europe: https://www.interactivebrokers.hu/en/accounts/broker-hu.php
Hong Kong: https://www.interactivebrokers.com.hk/en/accounts/broker.php
Singapore: https://www.interactivebrokers.com.sg/en/accounts/broker.php
India: https://www.interactivebrokers.co.in/en/accounts/broker.php
Australia: https://www.interactivebrokers.com.au/en/accounts/broker.php
About Interactive Brokers Group, Inc.:
Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities and foreign exchange around the clock on over 150 markets in numerous countries and currencies from a single unified platform to clients worldwide. We service individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation has enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. For the fifth consecutive year, Barron’s ranked Interactive Brokers #1 with 5 out of 5 stars in its March 25, 2022, Best Online Brokers Review.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230215005686/en/
Contact information
Interactive Brokers Group, Inc
Katherine Ewert, media@ibkr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
